外显子芯片分析识别影响胃癌风险的SPOCD1和BTN3A2变异
研究对1113例胃癌患者和1848名对照进行外显子芯片分析,在71,290个变异中筛选出24个候选变异,并在4687例额外胃癌病例和5780名对照中验证。发现SPOCD1基因低频错义变异rs112754928与胃癌风险降低相关(OR 0.56,P=3.48×10⁻⁸),BTN3A2附近变异rs1679709也与风险降低相关(OR 0.80,P=1.17×10⁻¹³),功能实验提示两基因参与胃癌发生。
要点
- SPOCD1 rs112754928与胃癌风险降低相关(OR 0.56,P=3.48×10⁻⁸)。
- BTN3A2附近rs1679709与胃癌风险降低相关(OR 0.80,P=1.17×10⁻¹³)。
- SPOCD1和BTN3A2在胃癌中过表达,敲除/缺失可抑制胃癌细胞恶性表型。
核心结论
- 1p35.2和6p22.1区域的遗传变异与胃癌风险相关,提示SPOCD1和BTN3A2参与胃癌发生。
研究设计与样本
- 外显子芯片分析纳入2006至2010年在中国医院收集的1113例胃癌患者和1848名体检无癌对照的血液DNA样本,分析71,290个变异(包括25,784个常见变异),选出24个变异在4687例额外胃癌病例和5780名对照中复制验证。
- 利用TCGA数据比较候选基因在肿瘤与正常胃组织中的表达,并行功能注释分析;使用永生化人胃上皮细胞系GES1和7种人胃癌细胞系进行转基因表达、小干扰RNA敲低、CRISPR/Cas9基因破坏或报告基因构建体表达评估,检测细胞增殖、集落形成、侵袭和迁移,并评估裸鼠异种移植瘤生长。
主要发现
- SPOCD1基因(1p35.2)低频错义变异rs112754928(编码p.Arg71Trp)与胃癌风险降低可重复相关(OR 0.56,P=3.48×10⁻⁸)。
- SPOCD1在胃肿瘤中过表达,敲除SPOCD1降低胃癌细胞增殖、侵袭活性、迁移及裸鼠异种移植瘤生长。
- 6p22.1变异rs1679709与胃癌风险降低相关(OR 0.80,P=1.17×10⁻¹³);保护等位基因rs1679709-A与周围单倍型rs2799077-T-rs2799079-C相关,降低该位点增强子活性从而减少BTN3A2表达。
- BTN3A2在胃肿瘤中过表达,缺失BTN3A2抑制胃癌细胞增殖、迁移和侵袭。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Several genetic variants have been associated with gastric cancer risk, although these account for only a fraction of cases of gastric cancer. We aimed to identify low-frequency and other genetic variants that determine gastric cancer susceptibility. METHODS: We performed exome array analysis of DNA in blood samples from 1113 patients with gastric cancer, collected at hospitals from 2006 to 2010 in China, and 1848 individuals without cancer (controls) undergoing physical examinations. Among 71,290 variants analyzed (including 25,784 common variants), 24 variants were selected and replicated in an analysis of DNA in blood samples from 4687 additional cases of gastric cancer and 5780 controls. We compared expression of candidate genes in tumor vs normal gastric tissues using data from TCGA and performed functional annotation analyses. An immortalized human gastric epithelial cell line (GES1) and 7 human gastric cancer lines were used to express transgenes, knock down gene expression (with small interfering RNAs), disrupt genes (using the CRISPR/Cas9 system), or assess expression of reporter constructs. We measured cell proliferation, colony formation, invasion, and migration, and assessed growth of xenograft tumors in nude mice. RESULTS: A low-frequency missense variant rs112754928 in the SPOC domain containing 1 gene (SPOCD1; encoding p.Arg71Trp), at 1p35.2, was reproducibly associated with reduced risk of gastric cancer (odds ratio, 0.56; P = 3.48 × 10-8). SPOCD1 was overexpressed in gastric tumors, and knockout of SPOCD1 reduced gastric cancer cell proliferation, invasive activity, and migration, as well as growth of xenograft tumors in nude mice. We also associated the variant rs1679709 at 6p22.1 with reduced risk for gastric cancer (odds ratio, 0.80; P = 1.17 × 10-13). The protective allele rs1679709-A correlated with the surrounding haplotype rs2799077-T-rs2799079-C, which reduced the enhancer activity of this site to decrease expression of the butyrophilin subfamily 3 member A2 gene (BTN3A2). BTN3A2 is overexpressed in gastric tumors, and deletion of BTN3A2 inhibited proliferation, migration, and invasion of gastric cancer cells. CONCLUSIONS: We have associated variants at 1p35.2 and 6p22.1 with gastric cancer risk, indicating a role for SPOCD1 and BTN3A2 in gastric carcinogenesis.
引用
- Zhu M, Yan C, Ren C, et al. Exome Array Analysis Identifies Variants in SPOCD1 and BTN3A2 That Affect Risk for Gastric Cancer. Gastroenterology. 2017. PMID: 28246015. doi:10.1053/j.gastro.2017.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。